Ethnic differences in warfarin maintenance dose requirement and its relationship with genetics

Pharmacogenomics

Volumn 9, Issue 9, 2008, Pages 1331-1346

  Schelleman, Hedi ^a   Limdi, Nita A ^b   Kimmel, Stephen E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b The University of Alabama at Birmingham   (United States)

Author keywords

APOE; CYP2C9; Maintenance dose; Pharmacogenetics; VKORC1; Warfarin

Indexed keywords

AMIODARONE; APOLIPOPROTEIN E; CYTOCHROME P450 2C9; OXIDOREDUCTASE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; VITAMIN K GROUP; WARFARIN;

AFRICAN AMERICAN; AMINO ACID SUBSTITUTION; ASIAN; BLEEDING; BLOOD CLOTTING; CAUCASIAN; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME ACTIVITY; ETHNIC DIFFERENCE; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ALGORITHM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MORTALITY; NEGRO; PHARMACOGENETICS; POPULATION GENETICS; PRESCRIPTION; RACE DIFFERENCE; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOEMBOLISM;

ETHNIC GROUPS; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; HUMANS; POLYMORPHISM, GENETIC; WARFARIN;

EID: 55449125520     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.9.1331     Document Type: Review

References (85)

1. Wittkowsky AK, Boccuzzi SJ, Wogen J, Wygant G, Patel P, Hauch O: Frequency of concurrent use of warfarin with potentially interacting drugs. Pharmacotherapy 24, 1668-1674 (2004).
2. Chiquette E, Amato MG, Bussey HI: Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch. Intern. Med. 158, 1641-1647 (1998).
3. Laupacis A, Albers G, Dalen J, Dunn MI, Jacobson AK, Singer DE: Antithrombotic therapy in atrial fibrillation. Chest 114, S579-S589 (1998).
4. Abusaada K, Sharma SB, Jaladi R, Ezekowitz MD: Epidemiology and management of new-onset atrial fibrillation. Am. J. Manag. Care 10, S50-S57 (2004).
5. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. JAMA 279, 1265-1272 (1998).
6. Rosamond WD, Folsom AR, Chambless LE et al.: Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort. Stroke 30, 736-743 (1999).
7. Dalen JE, Alpert JS: Natural history of pulmonary embolism. Prog. Cardiovasc. Dis. 17, 259-270 (1975).
8. Goldhaber SZ: Pulmonary embolism. N. Engl. J. Med. 339, 93-104 (1998).
9. Hyers TM, Agnelli G, Hull RD et al.: Antithrombotic therapy for venous thromboembolic disease. Chest 114, S561-S578 (1998).
10. Wittkowsky AK: Effective anticoagulation therapy: defining the gap between clinical studies and clinical practice. Am. J. Manag. Care 10, S297-S306; discussion S312-S317 (2004).
11. Hylek EM, D'Antonjo J, Evans-Molina C, Shea C, Henault LE, Regan S: Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke 37, 1075-1080 (2006).
12. Gullov AL, Koefoed BG, Petersen P: Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial fibrillation aspirin and anticoagulation. Arch. Intern. Med. 159, 1322-1328 (1999).
13. Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO: Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention. A population-based study. Ann. Intern. Med. 130, 14-22 (1999).
14. Hylek EM, Go AS, Chang Y et al.: Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N. Engl. J. Med. 349, 1019-1026 (2003).
15. White RH, Hong R, Venook AP et al.: Initiation of warfarin therapy: comparison of physician dosing with computer-assisted dosing. J. Gen. Intern. Med. 2, 141-148 (1987).
16. Wadelius M, Sorlin K, Wallerman O et al.: Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J. 4, 40-48 (2004).
17. Hirsh J, Dalen J, Anderson DR et al.: Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 119, S8-S21 (2001).
18. Dang MT, Hambleton J, Kayser SR: The influence of ethnicity on warfarin dosage requirement. Ann. Pharmacother. 39, 1008-1012 (2005).
19. Rosenberg NA, Pritchard JK, Weber JL et al.: Genetic structure of human populations. Science 298, 2381-2385 (2002).
20. Ramachandran S, Deshpande O, Roseman CC, Rosenberg NA, Feldman MW, Cavalli-Sforza LL: Support from the relationship of genetic and geographic distance in human populations for a serial founder effect originating in Africa. Proc. Natl Acad. Sci. USA 102, 15942-15947 (2005).
21. Conrad DF, Jakobsson M, Coop G et al.: A worldwide survey of haplotype variation and linkage disequilibrium in the human genome. Nat. Genet. 38, 1251-1260 (2006).
22. Haber LT, Maier A, Gentry PR, Clewell HJ, Dourson ML: Genetic polymorphisms in assessing interindividual variability in delivered dose. Regul. Toxicol. Pharmacol. 35, 177-197 (2002).
23. Lee CR, Goldstein JA, Pieper JA: Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in vitro and human data. Pharmacogenetics 12, 251-263 (2002).
24. Wu AH: Use of genetic and nongenetic factors in warfarin dosing algorithms. Pharmacogenomics 8, 851-861 (2007).
25. Kealey C, Chen Z, Christie J et al.: Warfarin and cytochrome P450 2C9 genotype: possible ethnic variation in warfarin sensitivity. Pharmacogenomics 8, 217-225 (2007).
26. Limdi NA, Goldstein JA, Blaisdell JA, Beasley TM, Rivers CA, Acton RT: Influence of CYP2C9 genotype on warfarin dose among African-Americans and European-Americans. Personalized Medicine 4, 157-169 (2007).
27. Momary KM, Shapiro NL, Viana MA, Nutescu EA, Helgason CM, Cavallari LH: Factors influencing warfarin dose requirements in African-Americans. Pharmacogenomics 8, 1535-1544 (2007).
28. Kimura R, Miyashita K, Kokubo Y et al.: Genotypes of vitamin K epoxide reductase, γ-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb. Res. 120, 181-186 (2007).
29. Sanderson S, Emery J, Higgins J: CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet. Med. 7, 97-104 (2005).
30. Veenstra DL, Blough DK, Higashi MK et al.: CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin. Pharmacol. Ther. 77, 353-364 (2005).
31. Cain D, Hutson SM, Wallin R: Assembly of the warfarin-sensitive vitamin K 2,3-epoxide reductase enzyme complex in the endoplasmic reticulum membrane. J. Biol. Chem. 272, 29068-29075 (1997).
32. Oldenburg J, von Brederlow B, Fregin A et al.: Congenital deficiency of vitamin K dependent coagulation factors in two families presents as a genetic defect of the vitamin K-epoxide-reductase-complex. Thromb. Haemost. 84, 937-941 (2000).
33. Bodin L, Horellou MH, Flaujac C, Loriot MA, Samama MM: A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance. J. Thromb. Haemost. 3, 1533-1535 (2005).
34. Harrington DJ, Underwood S, Morse C, Shearer MJ, Tuddenham EG, Mumford AD: Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1. Thromb. Haemost. 93, 23-26 (2005).
35. D'Ambrosio RL, D'Andrea G, Cafolla A, Faillace F, Margaglione M: A new vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with decreased stability of CYP2C9 enzyme. J. Thromb. Haemost. 5, 191-193 (2007).
36. Loebstein R, Dvoskin I, Halkin H et al.: A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 109, 2477-2480 (2007).
37. Rieder MJ, Reiner AP, Gage BF et al.: Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352, 2285-2293 (2005).
38. Takahashi H, Wilkinson GR, Nutescu EA et al.: Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet. Genomics 16, 101-110 (2006).
39. Schelleman H, Chen Z, Kealey C et al.: Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clin. Pharmacol. Ther. 81, 742-747 (2007).
40. Limdi NA, Arnett DK, Goldstein JA et al.: Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics 9, 511-526 (2008).
41. Aklillu E, Leong C, Loebstein R, Halkin H, Gak E: VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals. Blood 111, 3903-3904 (2008).
42. Lamon-Fava S, Sadowski JA, Davidson KW, O'Brien ME, McNamara JR, Schaefer EJ: Plasma lipoproteins as carriers of phylloquinone (vitamin K1) in humans. Am. J. Clin. Nutr. 67, 1226-1231 (1998).
43. Weintraub MS, Eisenberg S, Breslow JL: Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E. J. Clin. Invest. 80, 1571-1577 (1987).
44. Saupe J, Shearer MJ, Kohlmeier M: Phylloquinone transport and its influence on γ-carboxyglutamate residues of osteocalcin in patients on maintenance hemodialysis. Am. J. Clin. Nutr. 58, 204-208 (1993).
45. Visser LE, Trienekens PH, De Smet PA et al.: Patients with an ApoE ε4 allele require lower doses of coumarin anticoagulants. Pharmacogenet. Genomics 15, 69-74 (2005).
46. Kohnke H, Sorlin K, Granath G, Wadelius M: Warfarin dose related to apolipoprotein E (APOE) genotype. Eur. J. Clin. Pharmacol. 61, 381-388 (2005).
47. Kimmel SE, Christie J, Kealey C et al.: Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans. Pharmacogenomics J. 8, 53-60 (2008).
48. Lal S, Sandanaraj E, Jada SR et al.: Influence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients. Br. J. Clin. Pharmacol. 65, 260-264 (2008).
49. Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM: Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest 127, 2049-2056 (2005).
50. Gage B, Eby C, Johnson J et al.: Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. (2008) (Epub ahead of print).
51. Schelleman H, Chen J, Chen Z et al.: Dosing algorithms to predict warfarin maintenance dose in caucasians and African Americans. Clin. Pharmacol. Ther. (2008) (Epub ahead of print).
52. Wu AH, Wang P, Smith A et al.: Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 9, 169-178 (2008).
53. White, RH: The epidemiology of venous thromboembolism. Circulation 107, 14-18 (2003).
54. Snow V, Qaseem A, Barry P et al.: Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann. Intern. Med. 146, 204-210 (2007).
55. Ogg MS, Brennan P, Meade T, Humphries SE: CYP2C9*3 allelic variant and bleeding complications. Lancet 354, 1124 (1999).
56. Taube J, Halsall D, Baglin T: Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96, 1816-1819 (2000).
57. Margaglione M, Colaizzo D, D'Andrea G et al.: Genetic modulation of oral anticoagulation with warfarin. Thromb. Haemost. 84, 775-778 (2000).
58. D'Andrea G, D'Ambrosio RL, Di Perna P et al.: A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105, 645-649 (2005).
59. Loebstein R, Yonath H, Peleg D et al.: Interindividual variability in sensitivity to warfarin - nature or nurture? Clin. Pharmacol. Ther. 70, 159-164 (2001).
60. Vecsler M, Loebstein R, Almog S et al.: Combined genetic profiles of components and regulators of the vitamin K-dependent γ-carboxylation system affect individual sensitivity to warfarin. Thromb. Haemost. 95, 205-211 (2006).
61. Higashi MK, Veenstra DL, Kondo LM et al.: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287, 1690-1698 (2002).
62. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R: Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin. Pharmacol. Ther. 72, 702-710 (2002).
63. Hillman MA, Wilke RA, Caldwell MD, Berg RL, Glurich I, Burmester JK: Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics 14, 539-547 (2004).
64. Kamali F, Khan TI, King BP et al.: Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol. Ther. 75, 204-212 (2004).
65. Madelius M. Chen LY, Eriksson. N et al.: Association of warfarin dose with genes involved in its action and metabolism. Hum. Genet. 121, 23-34 (2007).
66. Herman D, Locatelli I, Grabnar I et al.: Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J. 5, 193-202 (2005).
67. Herman D, Peternel P, Stegnar M, Breskvar K, Dolzan V: The influence of sequence variations in factor VII, γ-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb. Haemost. 95, 782-787 (2006).
68. Lindh JD, Lundgren S, Holm L, Alfredsson L, Rane A: Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clin. Pharmacol. Ther. 78, 540-550 (2005).
69. Sconce EA, Khan TI, Wynne HA et al.: The impact of CYP2C9 and VKORC1 genetic polymorphisin and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106, 2329-2333 (2005).
70. Sconce EA, Daly AK, Khan TI, Wynne HA, Karnali F: APOE genotype makes a small contribution to warfarin dose requirements. Pharmacogenet. Genomics 16, 609-611 (2006).
71. Cariquist JF, Horne BD, Muhlestein JB et al.: Genotypes of the cytochrome p450 isoform, CYT2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J. Thromb. Thrombolysis 22, 191-197 (2006).
72. Zhu Y, Sherman M, Reynolds KK et al.: Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin. Cbem. 53, 1199-1205 (2007).
73. Veenstra DL, You JH, Rieder MJ et al.: Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet. Genomics 15, 687-691 (2005).
74. Kosaki K, Yamaghishi C, Sato R et al.: 1173C>T polymorphism in VKORC1 modulates the required warfarin dose. Pediatr. Cardiol. 27, 685-688 (2006).
75. Obayashi K, Nakamura K, Kawana J et al.: VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin. Pharmacol. Ther. 80, 169-178 (2006).
76. Lee SC, Ng SS, Oldenburg J et al.: Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin. Pharmacol. Ther. 79, 197-205 (2006).
77. Tharn LS, Gob BC, Nafziger A et al.: A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin. Pharmacol. Ther. 80, 346-355 (2006).
78. Cho HJ, Sohn KH, Park HM et al.: Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients. Pharmacogenomics 8, 329-337 (2007).
79. Miao L, Yang J, Huang C, Shen Z: Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur. J. Clin. Pharmacol. 63, 1135-1141 (2007).
80. Tabrizi AR, Zehnbauer BA, Borecki IB, McGrath SD, Buchman TG, Freeman BD: The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J. Am. Coll. Surg. 194, 267-273 (2002).
81. Aquilante CL, Langaee TY, Lopez LM et al.: Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin. Pbarmacol. Ther. 79, 291-302 (2006).
82. Lima MV, Ribeiro GS, Mesquita ET, Victer PR, Vianna-Jorge R: CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients. Eur. J. Clin. Pharmacol. 64, 9-15 (2008).
83. Wadelius M, Chen LY, Downes K et al.: Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 5, 262-270 (2005).
84. Anderson JL, Horne BD, Stevens SM et al.: Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116, 2563-2570 (2007).
85. Wadelius M, Chen LY, Lindh ID et al.: The largest prospective warfarin-treated cohort supports genetic forecasting. Blood (2008) (Epub ahead of print).